This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-11. Anything still debated is marked as such rather than presented as settled.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
== Pharmacology == CTOP is described as a highly potent mu-opioid receptor antagonist. In mice, its analgesic effects are qualified as being more potent than naloxone's, a well-known opioid antagonist typically used as an antidote in humans. Additionally, CTOP appears to lack significant affinity at the delta and kappa opioid receptors, suggesting that this peptide is selective for the μ receptor.
Courtaulds purchased the patents for this process in 1904, leading to significant growth of viscose fiber production. By 1931, expiration of patents for the viscose process led to its adoption worldwide. Global production of regenerated cellulose fiber peaked in 1973 at 3,856,000 tons. Regenerated cellulose can be used to manufacture a wide variety of products. While the first application of regenerated cellulose was as a clothing textile, this class of materials is also used in the production of disposable medical devices as well as fabrication of artificial membranes.
== Publications == J. Kopeček, J. Yang, "Polymer Nanomedicines". Advanced Drug Delivery Reviews 156, 40–66 (2020) L. Li, Y. Li, C.-H. Yang, D.C. Radford, J. Wang, M. Janát-Amsbury, J. Kopeček, J. Yang, "Inhibition of Immunosuppresive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking". Advanced Functional Materials 30:1908961 (2020) L. Li, J. Wang, Y. Li, D.C. Radford, J. Yang, J. Kopeček, "Broadening and Enhancing Functions of Antibodies by Self-Assembling Multimerization at Cell Surface". ACS Nano 13, 11422–11432 (2019) J. Yang, L. Li, J. Kopeček, "Biorecognition: A Key to Drug-free Macromolecular Therapeutics". Biomaterials 190–191, 11–23 (2019) J. Wang, L. Li, J. Yang, P.M. Clair, M. Glenn, D.M. Stephens, D.C. Radford, K.M. Kosak, M.W. Deininger, P.J. Shami, J. Kopeček, "Drug-free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction by Pretreatment with Gemcitabine". Nanomedicine: Nanotechnology, Biology and Medicine 16, 217–225 (2019). J. Yang, R. Zhang, H. Pan, Y. Li, Y. Fang, L. Zhang, J. Kopeček, "Backbone Degradable HPMA Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts". Molecular Pharmaceutics 14, 1384–1394 (2017) J.M. Hartley, T.-W. Chu, E.M. Peterson, R. Zhang, J. Yang, J. Harris, J.
Several approaches have been developed to analyze the location of organelles, genes, proteins, and other components within cells. A gene ontology category, cellular component, has been devised to capture subcellular localization in many biological databases. Microscopic pictures allow for the location of organelles as well as molecules, which may be the source of abnormalities in diseases. Finding the location of proteins allows us to predict what they do. This is called protein function prediction. For instance, if a protein is found in the nucleus it may be involved in gene regulation or splicing. By contrast, if a protein is found in mitochondria, it may be involved in respiration or other metabolic processes. There are well developed protein subcellular localization prediction resources available, including protein subcellular location databases, and prediction tools.
Catherine E. Costello is the William Fairfield Warren distinguished professor in the department of biochemistry, Cell Biology and Genomics, and the director of the Center for Biomedical Mass Spectrometry at the Boston University School of Medicine. Catherine E. Costello attended the Emmanuel College in Boston for her undergraduate studies in chemistry, and minors in mathematics and physics. She received a Master of Science (1967) and a PhD from Georgetown University (1971). After graduation, she did post-doctoral research with Klaus Biemann at Massachusetts Institute of Technology.
Sources: en.wikipedia.org
Inositol nicotinate, also known as inositol hexanicotinate or inositol hexaniacinate, is a compound of niacin (vitamin B3) and inositol. It is marketed in the United States as a "no-flush" form of niacin in dietary supplements. When ingested, inositol nicotinate breaks down into inositol and niacin. The niacin component helps widen blood vessels (vasodilation), lowers blood lipid levels (including cholesterol), and inhibits a protein involved in blood clotting. Inositol nicotinate is used to treat blood circulation problems, including: Raynaud's phenomenon Intermittent claudication Some research shows it can improve symptoms of Raynaud's phenomenon over several weeks. However, its effectiveness in treating other conditions like: High cholesterol High blood pressure Leg pain during exercise (due to poor circulation) remains unclear, with studies producing mixed results. Other proposed uses, such as for: Migraines Psoriasis Restless legs syndrome have insufficient supporting evidence. Inositol nicotinate is generally safe when taken by mouth, but possible side effects include:
Depending on the surroundings the optimal pH varies from 8 in the cytoplasm to 8.3 in the nucleus. The GLD-2 protein together with 136 proteins more, is involved in the molecular process of hematopoietic progenitor cell differentiation, in the human proteome. This is the process in which precursor cell type acquires the specialized features of a hematopoietic progenitor cell, a kind of cell types including myeloid progenitor cells and lymphoid progenitor cells.
=== Production of other elements === Americium is a starting material for the production of other transuranic elements and transactinides – for example, 82.7% of 242Am decays to 242Cm and 17.3% to 242Pu. In the nuclear reactor, 242Am is also up-converted by neutron capture to 243Am and 244Am, which transforms by β-decay to 244Cm:
to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. when already being treated with saxagliptin and dapagliflozin.
Sources: en.wikipedia.org
== Further reading == Nakagawa, Allen S., LIMS implementation and management, Cambridge: Royal Society of Chemistry, 1994 Liscouski, Joe, Laboratory and Scientific Computing a Strategic Approach, John Wiley & Sons, New York, 1995 Gibbon, Gerst, "A Brief History of LIMS", Laboratory Automation and Information Management 1996, 32(1), 1-5 Myers, J. D.; Fox-Dobbs, C.; Laird, J.; Le, Dai; Reich, D.; Curtz, T., "Electronic laboratory notebooks for collaborative research", In Proceedings of the 5th International Workshops on Enabling Technologies: Infrastructure for Collaborative Enterprises (WET ICE'96) (WET-ICE '96) IEEE Computer Society, Washington, DC, USA, 1996, 47-. Paszko, Christine; Pugsley, Carol, "Considerations in selecting a laboratory information management system (LIMS)", American Laboratory, 2000, 32(18), 38-42 Paszko, Christine; Turner, Elizabeth; Hinton, Mary D., Laboratory Information Management Systems, Revised & Expanded.
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
Soft tissue is tissue in the body that connects and surrounds or supports internal organs and bones, and includes muscle, tendons, ligaments, fat, fibrous tissue, lymph and blood vessels, fasciae, and synovial membranes. Soft tissue is not hardened by the processes of ossification or calcification such as bones and teeth. It is sometimes defined by what it is not – such as "nonepithelial, extraskeletal mesenchyme exclusive of the reticuloendothelial system and glia".
== History == The use of iboga in African spiritual ceremonies was first reported by French and Belgian explorers in the 19th century, beginning with the work of French naval physician and explorer of Gabon Marie-Théophile Griffon du Bellay. The first botanical description of the Tabernanthe iboga plant was made in 1889. Ibogaine was first isolated from T. iboga in 1901 by Dybowski and Landrin and independently by Haller and Heckel in the same year using T. iboga samples from Gabon. Complete synthesis of ibogaine was accomplished by G. Büchi in 1966. Since then, several other synthesis methods have been developed. Use of low doses of ibogaine (e.g. 10–30 mg/day) as a stimulant and "anti-fatigue" drug in the treatment of conditions like "cardiac atony", neurasthenia, and convalescence was advocated by French researchers in 1905. From the 1930s to 1960s, ibogaine was sold in France as Lambarène, an extract of the Tabernanthe manii plant, and promoted as a mental and physical stimulant. It was formulated at doses of 200 mg extract containing low doses of 4 to 8 mg ibogaine per tablet. The drug enjoyed some popularity among post-World War II athletes. Lambarène was withdrawn from the market in 1966 when the sale of ibogaine-containing products became illegal in France. Another formulation was Iperton, which contained Tabernanthe iboga extract 40 mg per dose unit. In 2008, Mačiulaitis and colleagues stated that in the late 1960s, the World Health Assembly classified ibogaine as a "substance likely to cause dependency or endanger human health". The U.S.
== Mechanism of action == Abatacept is a soluble CTLA-4 analog that prevents antigen-presenting cells (APCs) from delivering the co-stimulatory signal. This prevents the T cells from being fully activated, and even downregulates them. Simple signaling without co-stimulation allows the cell to recognize the primary signal as "self" and not ramp-up responses for future responses as well. In order for T cells to be activated and attack an antigen, that antigen must be presented to the T cell by an APC. That activation requires two signals (one of which is called co-stimulatory signal or signal 2): For signal 1, the APC must bind the antigen to a major histocompatibility complex (MHC) molecule, bring that complex to its surface, and present it to the T cell receptor on the surface of the T cell. For signal 2, the APC must present a B7 protein (CD80 or CD86) on its cell surface to a CD28 protein on the surface of the T cell. These two signals activate the T cell. Without signal 2, the T cell will not be activated, and will become anergic. Abatacept, which consists of a fusion protein of the extracellular domain of CTLA-4 and human IgG1, binds to the B7 protein on the APC and prevents it from delivering the co-stimulatory signal to the T cell.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.